Diabetes Type 2

 
New Novo Nordisk Combination Rx Better than Components for T2D, Weight Loss
August 23, 2022

Phase II clinical trial shows a fixed dose combination of semaglutide/cagrilintide reduces HbA1c and weight much better than either drug alone.

Seen in the ED: Diarrhea and BUQ Pain
August 23, 2022

The woman is in her mid-fifties, diarrhea has been persistent for 10 days and BUQ pain for 2 days. What does the CT show? What's your diagnosis?

Comorbidity Burden in T2D Patients Varies Widely, Becomes More Diverse Over Time
August 11, 2022

Analysis of 224 000 type 2 diabetes patients over 2 decades suggests the need for "revised care pathways" that better reflect the myriad causes of persistent morbidity.

Time-restricted Eating Could Improve Glucose Homeostasis, Other Metabolic Measures in Patients with Type 2 Diabetes
July 26, 2022

Food consumption confined to a 10-hour period for adults with T2D led to increased time in range and lowered nocturnal and fasting glucose.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes
July 22, 2022

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

7 New Drugs Approved for Primary Care: Q2 2022
July 07, 2022

From type 2 diabetes to chronic yeast infection, we have picked the top 7 FDA-approved drugs every primary care physician should know about from the second quarter.

Patients with Diabetes Face Higher Risk for Left-sided Valvular Stenotic Lesions
June 14, 2022

A new study found patients with T1D and T2D had a greater risk for stenotic lesions, whereas risk for valvular regurgitation was lower in those with T2D.

Flash CGM Increases Time in Range for T2D Patients on Noninsulin Therapies Not at Goal HbA1c
June 10, 2022

ADA 2022: Use of flash continuous glucose monitoring in T2D patients not on insulin also reduced HbA1c and glycemic variability, a new study finds.

Continuous Glucose Monitoring Linked to Better Glycemic Control, Reduced Hospitalizations in Study of Veterans Health Administration Data
June 08, 2022

ADA 2022: Large national study found that CGM use had a positive effect on glycemic control and acute complications in T2D in the Veterans Health Administration.

Glycemic Variability with Tirzepatide Significantly Lower vs Degludec as Assessed by CGM
June 08, 2022

ADA 2022. Tirzepatide was associated with significantly greater TIR, many fewer episodes of hypoglycemia, and less glycemic excursion vs insulin degludec in SURPASS-3 CGM.